NCT02100813View on ClinicalTrials.gov

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Actinic Keratosis
Interventions
DRUG

LEO 43204

DRUG

Placebo

Trial Locations (1)

30078

Gwinnett Clinical Research Center, Inc., Snellville

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY